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Classification of intronic and predicted missense
changes in the breast cancer susceptibility genes BRCA1
and BRCA2 remains a significant challenge for manage-
ment of patients carrying these variants. Defective
mRNA splicing is established as a pathway to disease,
and mRNA analysis of unclassified variants has been
shown to assist in classification and genetic counselling.
However the interpretation of splicing assay results can
be difficult, particularly for those variants that give rise
to aberrations in a background of naturally occurring
isoforms.
The ENIGMA (Evidence-based Network for the Inter-
pretation of Germline Mutant Alleles) consortium was
set up to facilitate research and improve research meth-
ods used to classify rare variants in the BRCA1 and
BRCA2 (and potentially other) breast cancer predisposi-
tion genes. ENIGMA has established a Splicing Working
Group, with stated purpose to pool the expertise of dif-
ferent active research groups to conduct large-scale stu-
dies that improve the clinical classification of likely
spliceogenic variants. An initial project of the Splicing
Working Group is to assess the consistency of protocols
and results obtained across the multiple participating
laboratories from Australia, Europe, UK and the USA. A
comparison of mRNA assay protocols in use across 21
labs has identified differences in source material for
RNA assays (cultured and uncultured lymphocytes, lym-
phoblastoid cell lines (LCLs) or constructs), differential
use of nonsense-mediated decay inhibitors, and numer-
ous differences in mRNA extraction, DNase treatment
and cDNA synthesis methods. A second phase of the
project is now underway to determine the impact of the
splicing assay methods routinely used by these labora-
tories on assay data and clinical interpretation of a
panel of variants. LCLs were selected from the kConFab
repository from carriers of a variant associated with sin-
gle major aberrant mRNA transcript absent in controls
(n=4); carriers of a variant associated with a complicated
aberrant mRNA splicing profile involving multiple tran-
scripts including naturally occurring isoforms (n=5);
female cancer-free controls (n=11). LCLs have already
been distributed to 15 of 20 participating sites, and
mRNA assays are underway. Preliminary results indicate
that major aberrations associated with several variants
mirror results previously observed for mRNA from
uncultured lymphocytes. In addition, there is evidence
for notable differences in expression of some isoforms
compared to results previously observed for RNA from
uncultured lymphocytes . This collaborative effort will
provide information to inform optimal standardised
mRNA splicing assay methodology, and to improve
guidelines for clinical interpretation of assay results. 1Genetic & Population Health Division, Queensland Institute of Medical
Research, Brisbane, Queensland, Australia
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